Table 2 MRI measurements
Part A: Whole group
MeasurementWhole groupNo progressionProgressionp Value
(n = 89)(n = 53)(n = 36)
median (IQR)median (IQR)median (IQR)
Brain
NBV baseline (ml)1467 (1422; 1513)1478 (1433; 1520)1466 (1400; 1499)ns
T2LL baseline (ml)3.9 (1.5; 11.9)3.6 (1.0; 8.5)5.1 (1.8; 21.3)ns
BHLL baseline (ml)0.3 (0.0; 0.9)0.3 (0.0; 0.7)0.4 (0.1; 1.5)ns
GADLL baseline (ml)0.0 (0.0; 0.2)0.0 (0.0; 0.2)0.0 (0.0; 0.2)ns
T2LL follow-up (ml)4.7 (1.9; 13.2)3.3 (1.2; 9.8)8.3 (2.4; 18.4)0.011
BHLL follow-up (ml)0.3 (0.0; 1.0)0.2 (0.0; 0.4)0.5 (0.1; 1.5)0.018
BHR baseline0.06 (0.00; 0.14)0.04 (0.00; 0.13)0.08 (0.02; 0.14)ns
BHR follow-up0.05 (0.01; 0.11)0.04 (0.00; 0.11)0.07 (0.03; 0.18)0.048
PBVC/year (%/year)−0.9 (−1.4; −0.4)−0.8 (−1.3; −0.3)−1.3 (−1.7; −0.5)0.011
Change in T2LL/year (ml/year)0.18 (−0.14; 0.69)0.18 (−0.14; 0.40)0.15 (−0.15; 1.27)ns
Percentage change in T2LL/year (%/year)6.1 (−4.7; 14.9)4.4 (−6.1; 12.8)7.4 (−1.8; 24.1)ns
Change in BHLL/year (ml/year)0.00 (−0.06; 0.05)0.00 (0.00; 0.02)0.00 (−0.06; 0.07)ns
Percentage change in BHLL/year (%/year)−3.3 (−19.5; 18.2)−6.0 (−23.2; 19.6)−2.4 (−13.1; 17.1)ns
Spinal cord
Number of focal lesions baseline3.0 (1.0; 4.0)2.0 (1.0; 4.5)3.0 (1.0; 4.0)ns
Number of segments with focal lesions baseline2.0 (1.0; 3.4)2.5 (0.8; 3.1)2.0 (1.0; 4.3)ns
Number of segments with diffuse lesions baseline0.0 (0.0; 0.0)0.0 (0.0; 0.0)0.0 (0.0; 0.0)ns
Number of focal lesions follow-up3.0 (1.0; 5.0)3.0 (1.0; 5.0)4.0 (2.0; 5.8)ns
Number of segments with focal lesions follow-up2.5 (1.0; 5.0)2.5 (1.0; 4.5)2.5 (2.0; 6.7)ns
Number of segments with diffuse lesions follow-up0.0 (0.0; 0.0)0.0 (0.0; 0.0)0.0 (0.0; 0.0)ns
Part B: Relapse-onset group
MeasurementWhole groupNo progressionProgressionp Value
(n = 74)(n = 49)(n = 25)
median (IQR)median (IQR)median (IQR)
Brain
NBV baseline (ml)1468 (1430; 1516)1479 (1440; 1520)1466 (1405; 1505)ns
T2LL baseline (ml)3.9 (1.7; 12.3)3.9 (1.3; 10.0)3.8 (1.9; 24.2)ns
BHLL baseline (ml)0.3 (0.0; 0.9)0.3 (0.0; 0.7)0.3 (0.0; 1.3)ns
GADLL baseline (ml)0.0 (0.0; 0.2)0.0 (0.0; 0.2)0.0 (0.0; 0.2)ns
T2LL follow-up (ml)4.7 (2.0; 14.2)4.1 (1.5; 10.2)8.5 (2.6; 22.5)0.034
BHLL follow-up (ml)0.2 (0.0; 1.1)0.2 (0.0; 0.6)0.8 (0.1; 1.6)0.018
BHR baseline0.06 (0.00; 0.13)0.04 (0.00; 0.14)0.07 (0.02; 0.13)ns
BHR follow-up0.05 (0.01; 0.12)0.04 (0.00; 0.11)0.07 (0.02; 0.18)ns
PBVC/year (%/year)−0.9 (−1.5; −0.4)−0.7 (−1.3; −0.3)−1.4 (−2.0; −0.8)0.006
Change in T2LL/year (ml/year)0.18 (−0.14; 0.69)0.18 (−0.14; 0.52)0.57 (−0.07; 1.78)ns
Percentage change in T2LL/year (%/year)6.5 (−4.6; 14.9)4.4 (−5.7; 12.8)8.6 (−1.2; 32.4)0.040
Change in BHLL/year (ml/year)0.00 (−0.06; 0.05)0.00 (−0.08; 0.04)0.06 (−0.06; 0.11)ns
Percentage change in BHLL/year (%/year)−2.5 (−19.5; 27.8)−5.8 (−24.2; 20.6)2.5 (−10.0; 35.9)ns
Spinal cord
Number of focal lesions baseline2.5 (1.0; 4.3)2.0 (1.0; 4.5)3.0 (1.0; 4.0)ns
Number of segments with focal lesions baseline2.0 (0.9; 3.1)2.0 (0.5; 3.3)2.0 (1.0; 3.4)ns
Number of segments with diffuse lesions baseline0.0 (0.0; 0.0)0.0 (0.0; 0.0)0.0 (0.0; 0.0)ns
Number of focal lesions follow-up3.0 (1.0; 5.0)3.0 (1.0; 5.0)4.0 (2.5; 6.0)ns
Number of segments with focal lesions follow-up2.5 (1.4; 5.1)2.5 (0.8; 4.5)2.5 (2.0; 6.9)ns
Number of segments with diffuse lesions follow-up0.0 (0.0; 0.0)0.0 (0.0; 0.0)0.0 (0.0; 0.1)ns
  • Progression, increase in EDSS of at least 1 point ; p value, Mann–Whitney U test was used to test for differences between the progression and the no progression group

  • BHLL, T1 hypointense lesion load (“black holes”); BHR, ratio BHLL/T2LL; GADLL, T1 gadolinium-enhancing lesion load; IQR, interquartile range (25%; 75%); NBV, normalised brain volume; PBVC, percentage brain volume change; T2LL, T2 hyperintense lesion load.